diphenhydramine hydrochloride; pseudoephedrine hydrochloride - Profile
What are the generic drug sources for diphenhydramine hydrochloride; pseudoephedrine hydrochloride and what is the scope of freedom to operate?
Diphenhydramine hydrochloride; pseudoephedrine hydrochloride
is the generic ingredient in one branded drug marketed by Parke Davis and is included in one NDA. Additional information is available in the individual branded drug profile pages.Summary for diphenhydramine hydrochloride; pseudoephedrine hydrochloride
| US Patents: | 0 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
US Patents and Regulatory Information for diphenhydramine hydrochloride; pseudoephedrine hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parke Davis | BENYLIN | diphenhydramine hydrochloride; pseudoephedrine hydrochloride | SOLUTION;ORAL | 019014-001 | Jun 11, 1985 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Diphenhydramine Hydrochloride + Pseudoephedrine Hydrochloride: Investment Scenario and Fundamentals
What is the drug and what does the market expect?
Diphenhydramine hydrochloride (DPH) plus pseudoephedrine hydrochloride (PSE) is a fixed-dose combination used primarily for short-term relief of cold and upper respiratory symptoms. The clinical value proposition is symptom control across nasal congestion and allergic-like manifestations. The economic reality is different: the active ingredients are off-patent in most jurisdictions, driving the market toward generic pricing, high manufacturing scale, and label-driven differentiation (dose forms, excipients, labeling language, and channel access).
Key inputs that shape investment fundamentals:
- Regulatory exposure is driven by pseudoephedrine controls (precursor rules) and pharmacy/retail dispensing mechanics.
- Pricing pressure is structurally elevated due to generic competition.
- Manufacturing and distribution dominate economics because product performance is tied to consistent solid-state quality and controlled substance supply chains (pseudoephedrine).
- Demand durability is linked to seasonal cold/flu cycles rather than disease-modifying growth.
What is pseudoephedrine’s regulatory and supply-chain constraint profile?
Pseudoephedrine is a regulated precursor. In the U.S., retail availability is governed by the Combat Methamphetamine Epidemic Act of 2005 (CMEA) amendments that restrict sales through limits at the point of sale and require tracking. U.S. consumers also face purchasing limits tied to daily and monthly totals. The key implication is that supply chain continuity and retailer compliance systems are critical to commercialization efficiency. The controls are enforced through the Retailer Sales Log and ID requirements implemented under CMEA. (U.S. FDA, 2024) [1]
What is the regulatory exposure for diphenhydramine?
Diphenhydramine hydrochloride is an antihistamine with sedating potential. The investment consequence is label vigilance: adverse event profile and consumer usage patterns can shift with formulation and labeling. From a commercialization standpoint, differentiators tend to be:
- Form factor (tablet vs capsule, immediate vs controlled release)
- Dosing regimen (frequency alignment with label)
- Sedation messaging and consumer compliance behavior
Diphenhydramine is not a precursor-regulated substance in the way pseudoephedrine is, so the higher friction typically attaches to PSE handling and retail controls rather than antihistamine manufacturing.
How do fixed-dose combinations affect IP and exclusivity?
The combination is a key constraint for high-moat IP strategies. For most branded combination products and many salt-based generic equivalents, the relevant patent estate is limited. Fixed-dose combinations can still show exclusivity through:
- Formulation patents (if any remain in the relevant markets)
- New dosage forms (if patents exist)
- Market exclusivity tied to new regulatory approvals (if they qualify)
However, for DPH + PSE, most economic participation in recent decades is typically generic. This means a “best-case” IP thesis is usually not a standard platform bet; it is a narrow line of sight into any remaining localized filings or specific regulatory exclusivities.
Because the question asks for investment scenario and fundamentals, the practical framework is therefore operational and channel-based rather than IP-driven.
Where does the revenue come from and how does pricing behave?
Revenue drivers:
- Seasonal demand for OTC cold remedies
- Channel breadth (mass retail, pharmacy chains, warehouse clubs, online marketplaces where compliant)
- Shelf placement and retailer planograms
- Form and dosing compliance that reduces customer returns and complaints
Pricing behavior:
- Generic competition compresses gross margins.
- Price elasticity increases when multiple AB-rated generics exist.
- Any differentiation usually shifts from “drug novelty” to service and packaging (count, dosing simplicity), and compliance positioning (retail process smoothness, consistent supply availability).
A credible investment model treats unit economics as a function of:
- COGS per dose
- Retail trade terms
- Regulatory/handling overhead for pseudoephedrine
- Inventory turns during seasonal peaks
What are the core “fundamentals” metrics for underwriting?
Market and product mechanics
- Seasonality: demand peaks during cold/flu seasons; off-season inventory and marketing spend matter.
- Retail constraints: pseudoephedrine sale limits reduce demand volatility but can tighten retailer purchasing patterns under compliance systems. (U.S. FDA, 2024) [1]
- Switching costs: low. Generics and alternative symptom products are easy substitutes.
Manufacturing and supply chain
- Salt-based solid dosage quality: dissolution and assay specs drive batch release stability and returns.
- Controlled precursor logistics: PSE procurement and inventory management can create working capital friction.
Commercial execution
- Compliance readiness: retailer and distributor systems for pseudoephedrine tracking and sales logs.
- Channel coverage: OTC distribution scale matters more than physician adoption.
How should an investor frame the investment scenario?
Scenario 1: Generic-focused OTC manufacturing/distribution
Best fit for companies with:
- Scale manufacturing
- Strong OTC distribution relationships
- Ability to operate through pseudoephedrine retail compliance workflows
Investment thesis:
- Margin stability through scale, procurement leverage, and forecast-driven inventory control.
- Growth through share gains in specific package counts, strengths, and regionally available generic lineups.
Main risks:
- Retailer demand compression and compliance friction
- Price war dynamics as additional generics enter or rotate supply
Scenario 2: Niche differentiation through formulation and packaging
Best fit for companies that can introduce:
- Improved dosing convenience (count and frequency aligned with label)
- More stable formulations across climates and shelf life requirements
- Packaging that fits compliance and OTC merchandising needs
Investment thesis:
- Defend margins through reduced logistics cost per dose and better sell-through predictability.
Main risks:
- Hard to sustain premium pricing if AB-rated substitution remains easy
Scenario 3: Any remaining brand-like positioning via regulatory or labeling advantages
This is usually limited for DPH + PSE because:
- Generics dominate typical price corridors
- Exclusivity windows depend on specific local regulatory filings
Investment thesis:
- If a company holds a credible advantage (rare), it is usually tied to a specific dossier in a specific jurisdiction, not a global moat.
Main risks:
- Fast price normalization after generic entry
What does the regulatory context imply for capital allocation?
Pseudoephedrine OTC rules change retailer ordering patterns. For investors, this means:
- Capital must cover working capital needs tied to precursor procurement and seasonal build plans.
- Supply chain contracts should be structured to avoid “stockouts in season,” when switching to alternative symptom-only products reduces addressable demand.
- Compliance capability is a cost center, not a one-time setup. Systems need maintenance as retailer processes update over time. (U.S. FDA, 2024) [1]
How do dosing and label considerations affect demand?
Diphenhydramine adds sedating effects. Demand can rise or fall depending on:
- Consumer preference shifts toward less sedating alternatives
- Safety messaging (driving, sleep, alcohol interactions)
- Product positioning by retailers and pharmacy clerks
Pseudoephedrine drives “works for congestion” perception. That component’s value can remain stable across seasons, but retailer constraints can still curb purchasing behavior.
In an underwriting model:
- Treat DPH as a usage-frequency stabilizer for multi-symptom perception
- Treat PSE as the primary congestion relief driver but also the compliance friction driver
What should an investor watch in the pipeline and entry risk map?
For a fixed-dose OTC combination, risk is primarily:
- Generic entry and reentry by manufacturers in the same AB therapeutic class
- Formulary-level substitution by retailers moving shelf space toward higher-turn SKUs
- Label or regulatory enforcement changes affecting purchasing behaviors
Watchpoints for entry risk:
- New ANDA approvals at scale (where available)
- Additions of new package sizes that disrupt expected sales curves
- Any jurisdiction-specific policy changes on precursor sales
Where are the main upside levers?
Upside levers typically come from:
- Share gains via reliability of supply and retailer relationship depth
- Lower unit costs through manufacturing efficiency and procurement scale
- Packaging optimization aligned to retailer merchandising and consumer preferences
- Channel expansion where compliance systems are robust
These levers are operational rather than clinical.
Where are the main downside risks?
Downside risks:
- Margin erosion from additional generic supply
- Disruption in pseudoephedrine supply chain inputs or logistics (working capital strain)
- Retailer compliance bottlenecks that reduce conversion rates
- Demand substitution to non-precursor or different-symptom OTC categories
What does a fundamentals model look like in practice?
A pragmatic investor model for DPH + PSE should separate: 1) OTC symptom category demand (seasonal baseline) 2) Competitive intensity (number of AB-rated offerings, retailer shelf space) 3) Unit economics (COGS, freight, compliance handling, rebates) 4) Working capital (precursor inventory timing around season) 5) Execution risk (stockouts vs overbuying)
Under this framework:
- If the company runs at scale with reliable precursor logistics, it can outperform even without IP.
- If procurement and compliance execution are weak, seasonal cycles amplify losses.
Key Takeaways
- Diphenhydramine hydrochloride plus pseudoephedrine hydrochloride is an OTC multi-symptom combination where operational execution beats IP strategy; margin drivers are manufacturing scale, distribution terms, and seasonal inventory control.
- Pseudoephedrine regulation is the central constraint: U.S. retail sale limits and tracking requirements under CMEA structure retailer purchasing and consumer conversion. (U.S. FDA, 2024) [1]
- Investment scenarios cluster into generic scale operators, niche formulation/packaging differentiators, and the rare case of localized regulatory advantage.
- Underwriting should emphasize working capital tied to precursor logistics, plus stockout risk vs price-war pricing pressure during the cold season.
FAQs
1) Is there meaningful patent exclusivity for diphenhydramine hydrochloride + pseudoephedrine hydrochloride?
No broad exclusivity expectation should drive an investor thesis for most markets; the economics typically track generic competition and OTC channel execution.
2) What regulatory action most directly impacts commercialization?
Pseudoephedrine retail rules and tracking requirements under U.S. CMEA affect how quickly and how much product retailers can sell and record. (U.S. FDA, 2024) [1]
3) Does diphenhydramine create special supply-chain risk?
Not in the precursor sense; the dominant constraint is pseudoephedrine handling and retail compliance.
4) What determines whether a generic producer wins on margins?
Scale manufacturing efficiency, consistent quality release, procurement leverage, and retailer trade terms that sustain volume through the season.
5) What is the biggest underwriting risk factor?
Seasonal inventory and working-capital timing. Stockouts reduce share and sales velocity; overbuying locks in inventory into a price-compressed generic environment.
References
[1] U.S. Food and Drug Administration. (2024). Information on pseudoephedrine and related products. https://www.fda.gov/
More… ↓
